NRG-GY014: A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma

Objective

This phase II trial studies how well tazemetostat works in treating patients with ovarian or endometrial cancer that has come back (recurrent). Chemotherapy drugs, such as tazemetostat, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

https://clinicaltrials.gov/ct2/show/NCT03348631

Location: Essentia Health Cancer Centers

Research Study Categories

• Adult Research Studies

Specialties

• Gynecologic Cancer

Contact

Cancer Clinical Trials at 218-786-3308 or 844-681-7944, [email protected]